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HIV-1 Nef is a multifunctional protein that exerts its activities through interactions with multiple cellular partners. Nef uses different domains
and mechanisms to exert its functions including cell surface down-modulation of CD4 and MHC-I receptors and activation of the serine/threonine
kinase PAK-2. We inserted tags at the C-terminus and proximal to the N-terminus of Nef and the effects on Nef's structure/function relationships
were examined. We discovered significant defects in MHC-I down-modulation with the insertion of HA/FLAG tags at either region. We also
found impaired PAK-2 activation with a C-terminal fusion with GFP. Interestingly, Nef-GFP and Nef-GH7 induced MHC-I down-modulation,
suggesting that the negative charge of the HA/FLAG tag could contribute to the observed defect. Together, these observations highlight elements
of Nef's functional complexity and demonstrate previously unsuspected structural requirements for PAK-2 activation and MHC-1 down-
modulation in Nef's flexible N- and C-terminal regions.
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Human immunodeficiency virus type 1 (HIV-1) Nef is a 27–
29 kDa accessory protein expressed at high levels early and
throughout the viral life cycle (Wei et al., 2003). Nef is
functionally complex (Arold and Baur, 2001; Foster et al., 2001;
Geyer et al., 2001; O'Neill et al., 2006) and is a major
determinant of viral pathogenicity (Kestler et al., 1991). Having
no known enzymatic activity, Nef instead likely functions as a
molecular adaptor, intercepting cellular signaling pathways via
protein–protein interactions (Arold and Baur, 2001; Geyer et
al., 2001; Roeth and Collins, 2006). Alleles of Nef have been
identified that are singly defective in three intensely studied in
vitro functions of Nef: MHC-1 downregulation, CD4 down-
regulation and PAK-2 activation (Carl et al., 2001; Foster et al.,
2001) which is consistent with Nef executing each of its
functions via interactions with distinct cellular factors or
complexes. Identification of the host cell proteins that interact
with Nef and relating different Nef complexes to Nef function is
a major area of investigation (Janardhan et al., 2004).⁎ Corresponding author. Fax: +1 214 648 0231.
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doi:10.1016/j.virol.2007.02.036The longest studied function of Nef is down-regulation of
cell surface CD4 (Garcia and Miller, 1991; Guy et al., 1987)
which is predicted to prevent super-infection of the host cell and
minimize the inhibitory effect of high CD4 levels on virus
production (Benson et al., 1993; Lama et al., 1999; Ross et al.,
1999). Nef is reported to act as a connector between the
cytoplasmic tail of CD4 and the cell's endocytotic machinery
(Bentham et al., 2003; Mangasarian et al., 1997). Host cell
binding partners for Nef potentially relevant for this function
include adaptor complexes (Bresnahan et al., 1999; Craig et al.,
1998; Greenberg et al., 1997, 1998a,1998b), a subunit of the
vacuolar ATPase complex (Geyer et al., 2002; Lu et al., 1998)
and the coatomer protein, β-COP (Benichou et al., 1994;
Janvier et al., 2001).
Another conserved function of Nef is down-modulation of
cell surface major histocompatibility class I (MHC-I) (Schwartz
et al., 1996) which reduces exposure of viral antigens to cyto-
toxic T-lymphocytes (Collins et al., 1998). While the mechan-
ism by which Nef effects this function is controversial, several
functional domains of Nef are reported to be required, including
an amphipathic α-helix (R17ERM20RRAEPA26), an acidic
region (E62–65) and a polyproline helix (P69/72/75/78) (Akari et
al., 2000; Greenberg et al., 1998a,1998b; Mangasarian et al.,
1999). The α-helix, acidic region and polyproline helix may be
Fig. 1. Diagram of Nefs modified with exogenous sequences. (A) SF2-HF or
NA7-HF Nefs; (B) SF2-GFP or NA7-GFP Nefs; (C) SF2-GH7 Nef; (D) HA-
SF2, HA/HA-SF2 or HA/FL/HA-SF2 Nefs. The dark line represents the coding
sequence of HIV-1 SF2 or NA7 Nef.
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MHC-I (Williams et al., 2005), and the acidic region is
postulated to also mediate an association with PACS-1
(Blagoveshchenskaya et al., 2002; Piguet et al., 2000).
A third function of Nef is the binding and activation of the
serine/threonine kinase p21-activated kinase 2 (PAK-2). The
mechanism of activation is not yet resolved, but is thought to
involve a multi-protein complex of Nef, PAK-2, β-PIX and
other unidentified proteins (Arora et al., 2000; Brown et al.,
1999; Renkema et al., 2001).
HIV-1 Nef has a genetically diverse and structurally flexible
N-terminal region of ∼70 residues followed by a relatively
well-conserved core domain of ∼130 residues and a C-terminal
tail of five amino acids (Arold and Baur, 2001). In contrast to
the long structured C-terminus of SIVmac239 Nef, the C-terminal
ends of HIV Nefs are short and flexible (Hochrein et al., 2006).
The core domain is the only part of Nef that adopts a stable
tertiary fold, and its structure has been solved by X-ray
crystallography (Arold et al., 1997) and NMR (Arold et al.,
2000). Solving the structure of full-length Nef has so far proved
difficult (Arold and Baur, 2001; Hochrein et al., 2006).
Functional roles of the N-terminal and C-terminal flexible
regions of HIV-1 Nef are not known. The N-terminal flexible
amino acids 21–34 in HIV-1 Nef may merely serve as a linker
between the two short alpha helices (amino acids 15–20 and
35–41) (Geyer et al., 1999). The C-terminal ∼25 amino acid
truncation of HIV-1 Nefs relative to SIVmac239 Nef is striking
since the C-terminus of SIVmac239 Nef is required for protein
stability (Garcia and Foster, 1996). If these regions have no
specific function in HIV-1 Nef, then they would be good
candidates for epitope tag placement. Therefore, we attached
peptide tags which varied in length and overall charge to the C-
terminus or proximal to the N-terminus of Nef. Attachment/
insertion of the peptide tags at these locations would not be
predicted to alter the structure of the Nef core domain or prevent
myristoylation of Nef, but our results demonstrate that
alterations at opposite sides of the molecule can result in
strongly impaired MHC-I down-modulation. Furthermore,
fusion of GFP to the C-terminal end of Nef yields a Nef fusion
protein defective in PAK-2 activation, and the severity of the
defect is isolate-dependent. These results demonstrate unex-
pected structural requirements for Nef function at the flexible
N- and C-terminal regions.
Results
To investigate possible effects of a C-terminal HA/FLAG
(HF) tag on Nef function, constructs expressing HIV-1 SF2 or
NA7 Nefs or Nefs tagged at the C-terminus (SF2, SF2-HF,
NA7, NA7-HF) (Fig. 1A) were transfected into 293 T cells and
cellular lysates were immunoprecipitated with polyclonal anti-
Nef antibodies or monoclonal anti-HA or anti-FLAG anti-
bodies. Immunoprecipitates were analyzed by in vitro kinase
assay to examine PAK-2 binding and activation by Nef (Sawai
et al., 1994). As depicted in Fig. 2A, a robust PAK-2 activation
signal was detected with SF2, SF2-HF, NA7 and NA7-HF Nefs
when cellular lysates were immunoprecipitated with anti-Nefantibodies (lanes 2–5). Unexpectedly, little PAK-2 activation
was detected when the same SF2-HF or NA7-HF Nefs were
immunoprecipitated with anti-HA (lanes 7, 8) or anti-FLAG
antibodies (lanes 10, 11). Although these results indicate that
the C-terminal HA/FLAG tag does not interfere with PAK-2
activation by Nef (compare lane 2 to lane 3 and lane 4 to lane 5),
PAK-2 activity was not co-immunoprecipitated with Nef using
anti-tag antibodies. Immunoprecipitations of tagged Nefs with
tag-specific antibodies were also analyzed by Western blot to
determine if the bulk of Nef was refractory to immunoprecipita-
tion or only the fraction of Nef bound to PAK-2 (Fig. 2B).
Tagged Nefs were efficiently immunoprecipitated with poly-
clonal anti-Nef antibodies (lanes 3, 5), anti-HA antibodies
(lanes 7, 8) and anti-FLAG antibodies (lanes 10, 11). It has been
previously reported that the minor fraction of Nef complexed to
activated PAK-2 is not detectable by Western blot or metabolic
labeling (Arora et al., 2000; Renkema et al., 2001; Sawai et al.,
1994). Therefore, the majority of Nef-HF can be immunopre-
cipitated with anti-tag antibodies, but PAK-2 activity is not co-
immunoprecipitated, suggesting that the C-terminal tags may
not form stable complexes with anti-tag antibodies when Nef is
bound to activated PAK-2. Alternatively, binding by anti-tag
antibodies may disrupt the Nef/PAK-2 activation complex
during immunoprecipitation of cell extracts, sterically hinder
the Nef/PAK-2 interaction or interfere with PAK-2 autopho-
sphorylation in the in vitro kinase assay.
Next, we evaluated the effect of the HA/FLAG C-terminal
tag on cell surface CD4 and MHC-I down-modulation.
Transduced CEM cells expressing SF2, SF2-HF, NA7 or
NA7-HF Nefs were analyzed by two-color flow cytometry for
cell surface CD4 and MHC-I. As shown in Fig. 3, both SF2-HF
and NA7-HF Nefs induced CD4 down-modulation. However, a
significant defect in MHC-I down-modulation was observed
with both SF2-HF and NA7-HF (the levels of MHC-I down-
modulation for SF2-HF and NA7-HF were 8 and 3%
respectively whereas the levels for SF2 and NA7 were 28 and
50%, respectively). Even though we noted reduced steady state
levels of NA7-HF compared to NA7 that could partially explain
the MHC-I defect for this isolate, the defect observed with SF2-
HF appears to result from the presence of the HF tag.
Since tagging Nef with short amino acid sequences at the
C-terminus resulted in functional defects in Nef, we were
interested in what effect a relatively large tag would have on Nef
function. Therefore, we fused GFP to the C-terminus of Nef
Fig. 3. CD4 and MHC-I down-modulation with C-terminal HA/FLAG (HF)
tagged SF2 and NA7 Nefs. CEM cells expressing SF2, SF2-HF, NA7 or NA7-
HF Nefs were analyzed for down-modulation of cell-surface MHC-I and CD4
using two-color flow cytometry (left panels). Nef expression in the transduced
CEM cells was confirmed by Western blotting of cellular lysates with anti-Nef
antibodies (right panel).
Fig. 2. Preferential co-immunoprecipitation of activated PAK-2 with C-terminal
HA/FLAG (HF) tagged SF2 and NA7 Nefs with anti-Nef antibodies. Plasmids
expressing SF2 or NA7 Nefs or Nefs tagged at the C-terminus with HA/FLAG
were transfected into 293T cells. Cellular lysates were immunoprecipitated with
the indicated antibodies and PAK-2 binding and activation was assayed by in
vitro kinase assay (A), or immunoprecipitates were analyzed by Western blot
with the mouse monoclonal anti-Nef antibody (EH1) to monitor the efficiency of
immunoprecipitation (B). The positions of the heavy and light chains of the
mouse antibodies used for immunoprecipitation are indicated to the right of the
blots. Protein expression levels and transfection efficiency were assayed by
Western blot of whole cell lysates using anti-Nef or anti-GFP antibodies (C).
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precipitate with active PAK-2, constructs expressing SF2, SF2-
GFP, NA7 and NA7-GFP Nef were transfected into 293T cells,
cellular lysates were immunoprecipitated with anti-Nef anti-
bodies and analyzed by in vitro kinase assay (Fig. 4A). Our
results indicated that fusing GFP to the C-terminal end of Nef
results in a reduction in the level of activated PAK-2 associated
with Nef (compare lane 2 to lane 3 and lane 4 to lane 5). The
impact of the GFP fusion on PAK-2 binding/activation wasfound to be different for the two Nefs used. SF2-GFP has 33±
5% (n=4) of the level of PAK-2 activation observed with wild
type SF2 (compare lanes 2, 3). NA7-GFP was found to be
essentially nonfunctional for PAK-2 activation (lane 5, n=4).
The defect in PAK-2 activation is not due to an inability of anti-
Nef antibodies to recognize the Nef-GFP fusion proteins, since
analysis of anti-Nef immunoprecipitates indicated that the bulk
of Nef was efficiently immunoprecipitated (Fig. 4A, lower
panel). The defect in PAK-2 activation may be due to the much
larger size of the GFP molecule compared to the HA/FLAG tag.
To assay cell surface receptor down-modulation, CEM cells
were transduced with vectors expressing Nef or Nef-GFP fusion
proteins (Fig. 4B). Cells were analyzed for down-modulation of
CD4 or MHC-I as well as GFP expression, to monitor down-
regulation in the transduced cell populations. Our results
indicate that SF2-GFP and NA7-GFP down-modulated cell
surface CD4 and MHC-I at comparable levels to SF2 and NA7,
respectively.
We considered the possibility that the highly negative charge
of the HA/FLAG tag (8 D, 2 K, 1 R) may contribute to the defect
observed with the ability of Nef-HF to down-modulate MHC-1,
since the much larger (249 amino acid) Nef-GFP fusion protein
was substantially more active than Nef-HF in this particular
function. Thus a tag devoid of negative charge GH7 (a tag with
one glycine and seven histidines) was added to the C-terminus of
SF2 Nef (Fig. 1C) and analyzed for the three different Nef
functions. To analyze PAK-2 activation, 293T cells were
transfected with constructs expressing either SF2 or SF2-GH7,
cellular lysates were immunoprecipitated with anti-Nef anti-
bodies and analyzed by in vitro kinase assay. Our results indicate
that SF2-GH7, like SF2-HF and NA7-HF, was fully functional
for PAK-2 activation (Figs. 2A and 5A) suggesting that the
impaired PAK-2 activation with Nef-GFP was due to the large
size of the GFP fusion protein. Similar results were obtained with
NA7-GH7 (data not shown). Interestingly, SF2-GH7 modestly
Fig. 4. Functional analysis of C-terminal Nef-GFP fusion proteins. (A) Empty vector (pCGCG) or plasmids expressing SF2, SF2-GFP, NA7 and NA7-GFP were
transfected into 293T cells. Cellular lysates were immunoprecipitated with polyclonal anti-Nef antibodies and PAK-2 binding and activation was assayed by in vitro
kinase assay (upper left panel). The efficiency of immunoprecipitation of the different Nefs using polyclonal anti-Nef antibodies was determined by Western blot of
immunoprecipitates (lower left panel). Protein expression levels and transfection efficiency were assayed by Western blot of whole cell lysates using mouse anti-Nef
and anti-GFP antibodies (right upper and lower panels). Note that the pCGCG vector constitutively expresses GFP (30 kDa). (B) CEM cells transduced with LXSN or
LnefSN (expressing Nef or Nef-GFP fusion proteins) were analyzed for down-modulation of cell-surface MHC-I and CD4 using two-color flow cytometry. Nef
expression levels in the transduced CEM cells were determined by Western blotting of cellular lysates with anti-Nef antibodies.
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analyze cell surface receptor down-modulation, CEM cells were
transduced with retroviral vectors expressing either SF2 or SF2-
GH7 and cell-surface down-modulation of both CD4 and MHC-I
was analyzed by two-color flow cytometry. SF2-GH7 was
functional for both CD4 and MHC-I down-modulation (45%
and 44%, respectively) (Fig. 5). Similar results were obtainedwith
NA7-GH7 (data not shown). These results demonstrate that the
deleterious effect of a C-terminal tag on Nef does not correlate
only to the length of the tag (a relatively short and a long tag (GH7
and GFP) modestly alteredMHC-1 down-modulation whereas an
intermediate length tag (HF) resulted in a severe defect). Rather,
these data suggest that the excess negative charge at the C-
terminus of Nef with the HF tag could contribute to the disruption
in MHC-I down-modulation.
Next, we were interested in analyzing the structural/
functional effects of insertion of exogenous sequences within
the N-terminal region of Nef. The N-terminus of Nef cannot be
modified since N-terminal myristoylation and membraneinsertion of Nef are required for all known Nef activities except
for the activation of Hck (Aiken and Trono, 1995; Briggs et al.,
2001; Chowers et al., 1994; Wiskerchen and Cheng-Mayer,
1996). Nefs are highly polymorphic with regard to length in the
17–26 amino acid region, and most of the variability is
accounted for by duplications of 2–10 amino acids (O'Neill et
al., 2006). There is a four amino acid duplication (RAEP) from
amino acid 22 to 25 in SF2 Nef but removal of these four amino
acids has no significant effect on PAK-2 activation, CD4 down-
modulation and enhancement of viral infectivity (O'Neill et al.,
2006). Importantly, these duplications do not disrupt the
function of the amphipathic alpha helix to their N-terminal
side (R17ERM20RRAEPA26) in MHC-I down-modulation
(O'Neill et al., 2006) (Table 1). Other regions of length
polymorphism exist in Nef but these consist of less common
short deletions (O'Neill et al., 2006). Therefore, the four amino
acid duplication in SF2 Nef was removed and replaced with tag
sequences, which include HA, HA/HA and HA/FLAG/HA
(Fig. 1D).
Fig. 5. Functional analysis of Nef containing a positive amino acid C-terminal
tag (SF2 Nef-GH7). (A) Empty vector (pcDNA3.1) or plasmids expressing SF2
or SF2-GH7 were transfected into 293T cells. Cellular lysates were
immunoprecipitated with polyclonal anti-Nef antibodies and PAK-2 binding
and activation was assayed by in vitro kinase assay (upper left panel). The
efficiency of immunoprecipitation of the Nefs using polyclonal anti-Nef
antibodies was determined by Western blot of separate immunoprecipitates
(lower left panel). Protein expression levels and transfection efficiency were
assayed by Western blot of the whole cell lysate using mouse anti-Nef and anti-
GFP antibodies (right upper and lower panels respectively). (B) CEM cells
expressing SF2 or SF2-GH7 were analyzed for down-modulation of cell-surface
MHC-I and CD4 using two-color flow cytometry. Nef expression levels in the
transduced CEM cells were determined by Western blotting of cellular lysates
with anti-Nef antibodies.
11A. Raney et al. / Virology 368 (2007) 7–16To examine PAK-2 activation using these internally tagged
Nefs, constructs expressing SF2, HA-SF2, HA/HA-SF2 and
HA/FLAG/HA-SF2 Nefs were transfected into 293T cells.
Cellular lysates were immunoprecipitated with anti-Nef, anti-
HA or anti-FLAG antibodies and immunoprecipitates were
analyzed for PAK-2 activation by in vitro kinase assay (Fig. 6A).
A strong PAK-2 activation signal was observed with all four
Nefs when lysates were immunoprecipitated with anti-Nef
antibodies (Fig. 6A, lanes 2–5). However, compared to the anti-
Nef immunoprecipitations, less than 10% of activated PAK-2
was co-immunoprecipitated with HA, HA/HA or HA/FLAG/
HA tagged SF2 Nefs using anti-HA antibodies (Fig. 6A, lanes
7–9) or anti-FLAG antibodies (lane 11). To determine if the
bulk Nef or just the Nef/PAK-2 complex was refractory toimmunoprecipitation with anti-tag antibodies, anti-Nef, anti-
HA or anti-FLAG immunoprecipitates were also analyzed by
Western blot (Fig. 6B). Our results indicate that all four Nefs
were efficiently immunoprecipitated with anti-Nef antibodies
(Fig. 6B, lanes 2–5), and that the HA/HA and HA/FLAG/HA
internally tagged Nefs were efficiently immunoprecipitated with
anti-HA antibodies (lanes 8–9). Interestingly, Nef with a single
HA tag was poorly immunoprecipitated by anti-HA antibodies
(lane 7). Furthermore, we were surprised to find that the FLAG
epitope of HA/FLAG/HA-Nef was poorly recognized by anti-
FLAG antibodies (lane 11), in contrast to the C-terminal HA/
FLAG tag (Fig. 2B, lanes 10–11). Altogether, these results
demonstrate that insertion of the HA, HA/HA or HA/FLAG/HA
tags at a position proximal to the N-terminus of Nef does not
inhibit PAK-2 activation by Nef. However, activated PAK-2 is
not co-immunoprecipitated with the internally tagged Nefs using
anti-tag antibodies. The HA/HA and HA/FLAG/HA tags may be
sterically hindered in the Nef/PAK-2 complex and not accessible
to anti-tag antibodies or the anti-tag antibodies may interfere
with PAK-2 autophosphorylation in the in vitro kinase assay.
However, bulk Nef is refractory to anti-HA immunoprecipitation
of the single HA-tagged Nef as well as anti-FLAG immunopre-
cipitation of the HA/FLAG/HA tagged Nef.
We then evaluated the effect of the N-terminal proximal
internal tags on CD4 and MHC-I down-modulation in
transduced CEM cells. As shown in Fig. 7, SF2, HA-SF2,
HA/HA-SF2 and HA/FLAG/HA-SF2 demonstrated similar
levels of CD4 down-modulation. In contrast, HA/HA-SF2 and
HA/FLAG/HA-SF2, but not HA-SF2, demonstrated significant
defects in MHC-I down-modulation compared to SF2 Nef.
Discussion
C-terminal addition of HA and FLAG tags to SF2 or NA7
Nefs resulted in proteins that were functional for PAK-2
activation but that did not co-immunoprecipitate active PAK-2
with anti-tag antibodies, even though the bulk population of Nef
was immunoprecipitated. These results may explain the reason
PAK-2 and other proteins such as β-PIX (Brown et al., 1999;
Renkema et al., 2001) were not detected in the large-scale
immunochemical purification of NA7-HF that did identify
DOCK2 and ELMO1 as Nef binding proteins (Janardhan et al.,
2004). A simple explanation is that the components of the Nef/
PAK-2 complex sterically hinder the interaction of the HA/
FLAG tag with anti-HA or anti-FLAG antibodies. That cellular
proteins bind to Nef in the C-terminal region is consistent with
mutational data demonstrating the functional significance of
F191 for PAK-2 activation (O'Neill et al., 2006). However,
another possibility is that the anti-tag antibodies disrupt the
binding of Nef-HF to PAK-2 during immunoprecipitation of
cell extracts or interfere with PAK-2 autophosphorylation in the
in vitro kinase assay.
Although the C-terminal HA/FLAG tag did not disrupt PAK-
2 activation or CD4 down-modulation, it did impact the ability
of SF2 Nef to down-regulate MHC-1. Even though this is also
the case for NA7-HF, the defect in MHC-1 down-regulation
with NA7-HF may be due to the reduced steady state levels of
Table 1
PAK-2 activation
anti-Nef IP
PAK-2 activation
anti-tap IP
CD4 down-modulation MHC-1 down-modulation
Wild-type SF2 ++ Not done ++ ++
NA7 + Not done +++ +++
SF2-HF ++ − +++ +
NA7-HF + − ++ −
C-terminal
tag/fusion
SF2-GFP + Not done ++ ++
NA7-GFP − Not done +++ ++
SF2-GH7 +++ Not done ++ +
NA7-GH7 + Not done +++ ++
Internal tag HA-SF2 +++ − ++ ++
HA/HA-SF2 +++ − ++ +
HA/FL/HA-SF2 +++ − ++ +
+, ++, +++=relative activity, −=defective.
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SF2 Nef with the C-terminal HF tag may be a result of steric
hindrance and/or excess negative charge. To determine whether
Nef is intolerant to large amino acid additions to its C-terminus,
we functionally characterized two Nef-GFP fusion proteins.
Nef proteins fused at the C-terminus with GFP have been
used to follow the localization of Nef in lipid rafts during
immunological synapse formation (Fenard et al., 2005),
analyze the effect of Nef on calcium release from intracellular
stores (Fenard et al., 2005), determine the role of Nef's
dileucine sorting motif in its subcellular distribution (Craig et
al., 2000), correlate the intracellular localization of Nef with
CD4 down-modulation (Greenberg et al., 1997) and demon-
strate co-localization of Nef with MHC-I in the perinuclear
region of cells (Williams et al., 2002). In our studies, Nef-GFP
fusion proteins were fully functional for CD4 down-modulation
and partially functional for MHC-I down-modulation. How-
ever, fusion of GFP to the C-terminus of both NA7 and SF2
resulted in defective PAK-2 activation by Nef (SF2-GFP
resulted in approximately a third of the activity as SF2, and
NA7-GFP was essentially nonfunctional). Western blot analysis
indicates that these differences in PAK-2 activation are not due
to different levels of protein expression or inability of the
polyclonal anti-Nef antibody to efficiently immunoprecipitate
Nef-GFP. Fusion of the GFP protein may sterically hinder the
interaction of the critical phenylalanine residue at position 191
of Nef with PAK-2 or other proteins involved in the activation
of PAK-2 by Nef.
Conversely, the ability of SF2-GFP and NA7-GFP to down-
modulate MHC-I suggests that the defect in MHC-I down-
modulation observed with SF2-HF and NA7-HF is not due only
to steric hindrance. An alternative explanation for the defect
may be the highly negative charge of the HF tag (8 D, 2 K, 1 R).
We tested this hypothesis by functionally analyzing Nef-GH7.
SF2-GH7 and NA7-GH7 were found to be functional for MHC-I
down-regulation, suggesting an altered conformation or asso-
ciation of Nef with C-terminal negative charges that are
incompatible with MHC-I down-modulation. However, the
size of the tag may contribute to the defect, since the HF tag is
28 amino acids whereas the GH7 tag is only eight amino acids.
SF2-GH7 and NA7-GH7 were fully functional for PAK-2 acti-
vation (Fig. 5 and data not shown), confirming our hypothesisthat the defect with SF2-GFP may be due to C-terminal addition
of the large fusion protein.
Deletion of the RAEP22–25 duplication in SF2 has a
negligible or no effect on any of the Nef functions studied
(O'Neill et al., 2006). Furthermore, analysis of a compilation of
1643 Nef sequences yielded a large number of Nefs with 2–10
amino acid duplications in the 17–26 amino acid region
(O'Neill et al., 2006). Since this region can tolerate duplica-
tions, we anticipated that Nef function would be minimally
disrupted by replacement of the RAEP duplication in SF2 with a
peptide tag. This was the case for the single HA tag insertion of
nine amino acids. However, anti-HA immunoprecipitations and
Western blot analysis indicated that the single HA tag was
poorly recognized by anti-HA antibodies. Thus, we inserted
HA/HA or HA/FLAG/HA peptide tags at amino acid 24. Nefs
containing these tags, although efficiently immunoprecipitated
with anti-HA antibodies, demonstrated a significant defect in
MHC-I down-modulation. The reverse correlation between
antibody recognition and MHC-I down-regulation exhibited
by HA-SF2 Nef and HA/HA or HA/FLAG/HA-SF2 Nefs sug-
gests previously undetected conformational constraints in the
N-terminal region of Nef that are important for its ability to
down-regulate MHC-I. These results may be explained by an
interaction between the first α helix (R17ERM20RRAEPA26)
and the ordered core of the Nef protein or another protein which
is required for MHC-I down-regulation. In fact, deletions of this
helix or mutation of M20 to A have been shown to be deleterious
to MHC-I down-regulation (Akari et al., 2000; Blagovesh-
chenskaya et al., 2002; Mangasarian et al., 1999; Williams et al.,
2005). An alternate hypothesis would be that the first α helix
has several arginine residues positioned to enable interaction
with phospholipids in the cellular membrane (Arold and Baur,
2001). Addition of the negative HA/HA and HA/FLAG/HA
tags within the membrane anchor of Nef could interfere with
Nef's association with the membrane.
PAK-2 activity was co-immunoprecipitated with HA/HA-
SF2 Nef and HA/FLAG/HA-SF2 Nefs when lysates were
immunoprecipitated with anti-Nef antibodies. However, less
than 10% of the PAK-2 activity was immunoprecipitated when
anti-HA antibodies were used for immunoprecipitation, despite
the fact that these antibodies efficiently immunoprecipitated
the bulk of Nef. These results are strikingly similar to those
Fig. 6. Co-immunoprecipitation of activated PAK-2 with Nefs containing HA,
HA/HA or HA/FLAG/HA tags inserted at position 24 with anti-Nef and anti-tag
antibodies. Empty vector (pcDNA3.1) or plasmids expressing SF2 or SF2
containing the internally inserted tags HA, HA/HA or HA/FLAG/HA were
transfected into 293T cells. Cellular lysates were immunoprecipitated with the
indicated antibodies and PAK-2 binding and activation was assayed by in vitro
kinase assay (A), or anti-tag immunoprecipitates were analyzed by Western blot
with mouse anti-Nef antibodies (EH1) to monitor the efficiency of immuno-
precipitation (B). The positions of the heavy and light chains of the mouse
antibodies used for immunoprecipitation are indicated to the right of the blots.
Protein expression levels and transfection efficiency were assayed by Western
blot of the whole cell lysate using mouse anti-Nef and anti-GFP antibodies (C).
Fig. 7. CD4 and MHC-I down-modulation with Nefs containing HA, HA/HA or
HA/FLAG/HA tags inserted at position 24. CEM cells transduced with LXSN or
LnefSN (expressing SF2 or SF2 Nefs with internal tags) were analyzed for
down-modulation of cell-surface MHC-I and CD4 using two-color flow
cytometry (left panel). Nef expression levels in the transduced CEM cells were
determined byWestern blotting of cellular lysates with anti-Nef antibodies (right
panel).
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were unanticipated, more studies including the possible role of
the N-terminal region of Nef on PAK-2 activation will be
required to elucidate these findings.
In summary, peptide tags were added to Nef's C-terminus or
proximal to the N-terminus and the effect of these sequence
modifications on Nef function was determined. We discovered
disruptions in Nef function with respect to MHC-I down-
modulationwith the addition of peptide tags to either region. The
defect with MHC-I down-modulation with the C-terminal
modifications was found to be mostly due to the negative
charge of the added sequences and not to their relative size. This
finding is consistent with the +2 net charge on the 27 amino acid
C-terminal extension found in SIVmac239 Nef and with the
observation that the intact C-terminus of SIVmac239 Nef is
required for MHC-1 down-regulation (Swigut et al., 2004). We
also observed disruption of PAK-2 activation with a C-terminal
GFP fusion protein. These results are consistent with a
functional model of Nef effecting multiple functions by forming
distinct complexes with host cell proteins (Arold and Baur,
2001; Geyer et al., 2001). Furthermore, these results suggest that
regions of Nef near its N and C-terminus have subtle structural
constraints imposed by one or more of these complexes.
Materials and methods
Cell lines and culture conditions
293T cells were cultured in Dulbecco's modified Eagle's
medium (DMEM; Cellgro, Herndon, VA) supplemented with
10% fetal bovine serum (FBS; Cellgro), 100 IU penicillin/ml,
100 μg streptomycin/ml and 2 mM glutamine (Cellgro), and
were maintained at 37 °C in a humidified incubator with 10%
14 A. Raney et al. / Virology 368 (2007) 7–16carbon dioxide. CEM cells were cultured in RPMI 1640medium
supplemented with 10% FBS, 100 IU penicillin/ml, 100 μg
streptomycin/ml, 2 mM glutamine, and 1 mM sodium pyruvate
(Cellgro) andweremaintained at 37 °C in a humidified incubator
with 5% carbon dioxide.
Plasmid expression constructs, transfections and transductions
NA7 and NA7-HF (HF=DTYRYIANATYPYDVPDYAG-
DYKDDDDK) were obtained from Dr. Jacek Skowronski
(Janardhan et al., 2004). SF2, SF2-HF, SF2-GH7, SF2-GFP and
NA7-GFP were constructed using standard molecular biology
techniques. HA-SF2 Nef was cloned by introducing a BssHI
restriction site at amino acid 24 of SF2 Nef by site-directed
mutagenesis, converting E24Q. This made the downstream BlpI
restriction site unique. Complimentary oligos with overhangs
were made and annealed at ratio of 1:1. Serial dilutions of
annealed oligos were ligated with SF2 Nef E24Q cut with
BssHI and BlpI to yield HA-SF2 Nef (HA=9 amino acids,
YPYDVPDYA). HA/HA-SF2 Nef (HA/HA=19 amino acids,
YPYDVPDYAGYPYDVPDYA) and HA/FLAG/HA-SF2 Nef
(HA/FLAG/HA=29 amino acids, YPYDVPDYAGDYKDDD-
DKAGYPYDVPDYA) were made utilizing internal restriction
sites incorporated into HA and HA/HA oligos, respectively.
Modified nef sequences were transferred to the mammalian
expression vectors pcDNA3.1, pCG or pCGCG (Janardhan
et al., 2004) or the retroviral vector pLXSN (containing the
neomycin phosphotransferase gene) and sequenced. Insertion of
epitope tags was also verified by Western blot using antibodies
directed against HA or FLAG. Transient transfections of 293T
cells were performed using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) as per the manufacturer's instructions, with the
exception that due to the high level of expression of the pCGCG
and pCG plasmids, nanogram quantities (200–500) of these
particular plasmids were used for transfection. As a control
for transfection efficiency, pEGFP-N1 was included in the
transfection mix. After transfection (40–48 h), cells were
harvested for Western blot analysis (200 μg of protein) and
in vitro kinase assay (600 μg of protein). For transduction of
CEM cells, pEQPAM (2 μg) and pLXSN or various pLnefSNs
(2 μg) were co-transfected into 293T cells to generate am-
photropic vectors. At 40–48 h after transfection, the vector-
containing media were collected for transduction using standard
techniques.
Western blot analysis
HIV-1 Nef expression was determined using sheep poly-
clonal anti-HIV-1 Nef serum (1:3000) followed by horseradish
peroxidase (HRP)-conjugated rabbit anti-sheep immunoglobu-
lin G (IgG; 1:10,000; Chemicon International Inc., Temecula,
CA) or mouse anti-HIV-1 Nef antibodies (EH1; 1:10,000; AIDS
Research and Reference Program) followed by HRP-conjugated
goat anti-mouse IgG (1:10,000; Zymed, San Francisco, CA).
GFP expression was determined using mouse anti-GFP anti-
bodies (1:4000; Zymed) followed by HRP-conjugated goat anti-
mouse IgG.In vitro kinase assay and immunoprecipitations
The assay for the Nef-associated kinase was performed
essentially as described (Foster et al., 2001; Luo and Garcia,
1996; Sawai et al., 1994). HIV-1 Nef (and Nefs modified with
peptide tags or fusion proteins) were immunoprecipitated from
cellular lysates with sheep polyclonal anti-HIV-1 Nef serum,
mouse monoclonal anti-HA antibodies (Covance, Berkeley,
CA) or mouse anti-FLAG antibodies (M2; Sigma, Saint
Louis, MO). For the in vitro kinase assays, immunoprecipi-
tates bound to protein A beads were resuspended in kinase
assay buffer (50 mM Tris–HCl pH 7.5, 100 mM sodium
chloride, 5 mM magnesium chloride and 1% v/v 5 Triton
X-100). Subsequently, 30 μCi of γ-[32P]-ATP (Perkin Elmer,
Boston, MA) was added and reactions were incubated for
10 min at 30 °C. Kinase reactions were stopped by the
addition of EDTA (45 mM) and processed as previously
described (Arora et al., 2000). Alternatively, immunoprecipi-
tates bound to protein A beads were washed five times in lysis
buffer, eluted with 1× SDS sample buffer and analyzed by
Western blot.
Quantitation of in vitro kinase reactions
The in vitro kinase reactions were quantitated from at least
three different experiments using the Cyclone Storage Phosphor
System (Packard, Meriden, CT).
Flow cytometry analysis
For analysis of cell surface CD4 and MHC-I levels,
transduced cells (500,000) were first incubated with a mouse
monoclonal antibody recognizing anti-haplotype A1, A11, and
A26 MHC class I (One Lambda, Canoga Park, CA) for 20 min
on ice in the dark, and then the cells were washed twice in 2 ml
of ice-cold phosphate buffered saline containing 5% FBS. Cells
were then incubated with fluorescein isothiocyanate-labeled
goat anti-mouse IgG for 20 min on ice. Cells were washed as
indicated above and incubated for 20 min on ice with 2 μg of
mouse IgG, and washed again. Cells were then incubated with
phycoerythrin (PE)-conjugated IgG monoclonal antibody to
human CD4 (Exalpha, Maynard, MA) for 20 min on ice.
Stained cells were washed and analyzed on a Becton
Dickinson FACSCalibur instrument equipped with Cellquest-
Pro software. All fluorescence data were collected in log
mode. CEM cells transduced with LXSN served as the
positive control. For negative controls, mouse isotype anti-
body replaced anti-MHC class I, and PE-conjugated mouse
IgG (Exalpha) replaced PE-conjugated anti-CD4. In Fig. 3B,
cell surface down-modulation of CD4 was analyzed on the
GFP-positive cell population by staining cells with phycoer-
ythrin (PE)-conjugated IgG monoclonal antibody to human
CD4 (Exalpha, Maynard, MA). MHC-I cell surface levels
were analyzed on the GFP positive cell population using the
mouse monoclonal MHC class I antibody indicated above,
followed by allophycocyanin (APC)-conjugated goat anti-
mouse IgG.
15A. Raney et al. / Virology 368 (2007) 7–16Acknowledgments
We thank Jacek Skowronski for generously providing the
pCGCG, pCGCGNA7 and pCGNA7-HF plasmids and to James
Hoxie for the monoclonal anti-Nef antibody (EH1) that was
originally obtained through the NIH AIDS Research and
Reference Reagent Program. We greatly appreciate Michael
Melkus, Anja Wege and Laura Baugh for assistance with flow
cytometry and data analysis, and to Laura Baugh and Anja
Wege for assistance with cell transductions and maintenance of
cell lines. This work was supported by National Institutes of
Health grant AI-33331 (J.V.G.). Alexa Raney was supported in
part by National Institutes of Health training grant 5 F32
AI058541-03.References
Aiken, C., Trono, D., 1995. Nef stimulates human immunodeficiency virus type
1 proviral DNA synthesis. J. Virol. 69 (8), 5048–5056.
Akari, H., Arold, S., Fukumori, T., Okazaki, T., Strebel, K., Adachi, A.,
2000. Nef-induced major histocompatibility complex class I down-regu-
lation is functionally dissociated from its virion incorporation, enhance-
ment of viral infectivity, and CD4 down-regulation. J. Virol. 74 (6),
2907–2912.
Arold, S.T., Baur, A.S., 2001. Dynamic Nef and Nef dynamics: how structure
could explain the complex activities of this small HIV protein. Trends
Biochem. Sci. 26 (6), 356–363.
Arold, S., Franken, P., Strub, M.P., Hoh, F., Benichou, S., Benarous, R., Dumas,
C., 1997. The crystal structure of HIV-1 Nef protein bound to the Fyn kinase
SH3 domain suggests a role for this complex in altered T cell receptor
signaling. Structure 5 (10), 1361–1372.
Arold, S., Hoh, F., Domergue, S., Birck, C., Delsuc, M.A., Jullien, M., Dumas,
C., 2000. Characterization and molecular basis of the oligomeric structure of
HIV-1 nef protein. Protein Sci. 9 (6), 1137–1148.
Arora, V.K., Molina, R.P., Foster, J.L., Blakemore, J.L., Chernoff, J.,
Fredericksen, B.L., Garcia, J.V., 2000. Lentivirus Nef specifically activates
Pak2. J. Virol. 74 (23), 11081–11087.
Benichou, S., Bomsel, M., Bodeus, M., Durand, H., Doute, M., Letourneur, F.,
Camonis, J., Benarous, R., 1994. Physical interaction of the HIV-1 Nef
protein with beta-COP, a component of non-clathrin-coated vesicles
essential for membrane traffic. J. Biol. Chem. 269 (48), 30073–30076.
Benson, R.E., Sanfridson, A., Ottinger, J.S., Doyle, C., Cullen, B.R., 1993.
Downregulation of cell-surface CD4 expression by simian immuno-
deficiency virus Nef prevents viral super infection. J. Exp. Med. 177 (6),
1561–1566.
Bentham, M., Mazaleyrat, S., Harris, M., 2003. The di-leucine motif in the
cytoplasmic tail of CD4 is not required for binding to human immunode-
ficiency virus type 1 Nef, but is critical for CD4 down-modulation. J. Gen.
Virol. 84 (Pt. 10), 2705–2713.
Blagoveshchenskaya, A.D., Thomas, L., Feliciangeli, S.F., Hung, C.H.,
Thomas, G., 2002. HIV-1 Nef downregulates MHC-I by a PACS-1- and
PI3K-regulated ARF6 endocytic pathway. Cell 111 (6), 853–866.
Bresnahan, P.A., Yonemoto, W., Greene, W.C., 1999. Cutting edge: SIV Nef
protein utilizes both leucine- and tyrosine-based protein sorting pathways for
down-regulation of CD4. J. Immunol. 163 (6), 2977–2981.
Briggs, S.D., Scholtz, B., Jacque, J.M., Swingler, S., Stevenson, M., Smithgall,
T.E., 2001. HIV-1 Nef promotes survival of myeloid cells by a Stat3-
dependent pathway. J. Biol. Chem. 276 (27), 25605–25611.
Brown, A., Wang, X., Sawai, E., Cheng-Mayer, C., 1999. Activation of the
PAK-related kinase by human immunodeficiency virus type 1 Nef in
primary human peripheral blood lymphocytes and macrophages leads to
phosphorylation of a PIX-p95 complex. J. Virol. 73 (12), 9899–9907.
Carl, S., Greenough, T.C., Krumbiegel, M., Greenberg, M., Skowronski, J.,
Sullivan, J.L., Kirchhoff, F., 2001. Modulation of different humanimmunodeficiency virus type 1 Nef functions during progression to AIDS.
J. Virol. 75 (8), 3657–3665.
Chowers, M.Y., Spina, C.A., Kwoh, T.J., Fitch, N.J., Richman, D.D., Guatelli,
J.C., 1994. Optimal infectivity in vitro of human immunodeficiency virus
type 1 requires an intact nef gene. J. Virol. 68 (5), 2906–2914.
Collins, K.L., Chen, B.K., Kalams, S.A., Walker, B.D., Baltimore, D., 1998.
HIV-1 Nef protein protects infected primary cells against killing by
cytotoxic T lymphocytes. Nature 391 (6665), 397–401.
Craig, H.M., Pandori, M.W., Guatelli, J.C., 1998. Interaction of HIV-1 Nef with
the cellular dileucine-based sorting pathway is required for CD4 down-
regulation and optimal viral infectivity. Proc. Natl. Acad. Sci. U.S.A. 95
(19), 11229–11234.
Craig, H.M., Reddy, T.R., Riggs, N.L., Dao, P.P., Guatelli, J.C., 2000.
Interactions of HIV-1 nef with the mu subunits of adaptor protein complexes
1, 2, and 3: role of the dileucine-based sorting motif. Virology 271 (1), 9–17.
Fenard, D., Yonemoto, W., de Noronha, C., Cavrois, M., Williams, S.A.,
Greene, W.C., 2005. Nef is physically recruited into the immunological
synapse and potentiates T cell activation early after TCR engagement.
J. Immunol. 175 (9), 6050–6057.
Foster, J.L., Molina, R.P., Luo, T., Arora, V.K., Huang, Y., Ho, D.D., Garcia,
J.V., 2001. Genetic and functional diversity of human immunodeficiency
virus type 1 subtype B Nef primary isolates. J. Virol. 75 (4), 1672–1680.
Garcia, J.V., Foster, J.L., 1996. Structural and functional correlates between
HIV-1 and SIV Nef isolates. Virology 226 (2), 161–166.
Garcia, J.V., Miller, A.D., 1991. Serine phosphorylation-independent down-
regulation of cell-surface CD4 by nef. Nature 350 (6318), 508–511.
Geyer, M., Munte, C.E., Schorr, J., Kellner, R., Kalbitzer, H.R., 1999. Structure
of the anchor-domain of myristoylated and non-myristoylated HIV-1 Nef
protein. J. Mol. Biol. 289 (1), 123–138.
Geyer, M., Fackler, O.T., Peterlin, B.M., 2001. Structure–function relationships
in HIV-1 Nef. EMBO Rep. 2 (7), 580–585.
Geyer, M., Yu, H., Mandic, R., Linnemann, T., Zheng, Y.H., Fackler, O.T.,
Peterlin, B.M., 2002. Subunit H of the V-ATPase binds to the medium chain
of adaptor protein complex 2 and connects Nef to the endocytic machinery.
J. Biol. Chem. 277 (32), 28521–28529.
Greenberg, M.E., Bronson, S., Lock, M., Neumann, M., Pavlakis, G.N.,
Skowronski, J., 1997. Co-localization of HIV-1 Nef with the AP-2 adaptor
protein complex correlates with Nef-induced CD4 down-regulation. EMBO
J. 16 (23), 6964–6976.
Greenberg, M., DeTulleo, L., Rapoport, I., Skowronski, J., Kirchhausen, T.,
1998a. A dileucine motif in HIV-1 Nef is essential for sorting into
clathrin-coated pits and for downregulation of CD4. Curr. Biol. 8 (22),
1239–1242.
Greenberg, M.E., Iafrate, A.J., Skowronski, J., 1998b. The SH3 domain-binding
surface and an acidic motif in HIV-1 Nef regulate trafficking of class I MHC
complexes. EMBO J. 17 (10), 2777–2789.
Guy, B., Kieny, M.P., Riviere, Y., Le Peuch, C., Dott, K., Girard, M.,
Montagnier, L., Lecocq, J.P., 1987. HIV F/3′ orf encodes a phosphorylated
GTP-binding protein resembling an oncogene product. Nature 330 (6145),
266–269.
Hochrein, J.M., Wales, T.E., Lerner, E.C., Schiavone, A.P., Smithgall, T.E.,
Engen, J.R., 2006. Conformational features of the full-length HIV and SIV
Nef proteins determined by mass spectrometry. Biochemistry 45 (25),
7733–7739.
Janardhan, A., Swigut, T., Hill, B., Myers, M.P., Skowronski, J., 2004. HIV-1
Nef binds the DOCK2-ELMO1 complex to activate rac and inhibit
lymphocyte chemotaxis. PLoS Biol. 2 (1), E6.
Janvier, K., Craig, H., Le Gall, S., Benarous, R., Guatelli, J., Schwartz, O.,
Benichou, S., 2001. Nef-induced CD4 downregulation: a diacidic sequence
in human immunodeficiency virus type 1 Nef does not function as a
protein sorting motif through direct binding to beta-COP. J. Virol. 75 (8),
3971–3976.
Kestler III, H.W., Ringler, D.J., Mori, K., Panicali, D.L., Sehgal, P.K., Daniel,
M.D., Desrosiers, R.C., 1991. Importance of the nef gene for maintenance of
high virus loads and for development of AIDS. Cell 65 (4), 651–662.
Lama, J., Mangasarian, A., Trono, D., 1999. Cell-surface expression of CD4
reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-
inhibitable manner. Curr. Biol. 9 (12), 622–631.
16 A. Raney et al. / Virology 368 (2007) 7–16Lu, X., Yu, H., Liu, S.H., Brodsky, F.M., Peterlin, B.M., 1998. Interactions
between HIV1 Nef and vacuolar ATPase facilitate the internalization of
CD4. Immunity 8 (5), 647–656.
Luo, T., Garcia, J.V., 1996. The association of Nef with a cellular serine/
threonine kinase and its enhancement of infectivity are viral isolate
dependent. J. Virol. 70 (9), 6493–6496.
Mangasarian, A., Foti, M., Aiken, C., Chin, D., Carpentier, J.L., Trono, D.,
1997. The HIV-1 Nef protein acts as a connector with sorting pathways in
the Golgi and at the plasma membrane. Immunity 6 (1), 67–77.
Mangasarian, A., Piguet, V., Wang, J.K., Chen, Y.L., Trono, D., 1999. Nef-
induced CD4 and major histocompatibility complex class I (MHC-I) down-
regulation are governed by distinct determinants: N-terminal alpha helix and
proline repeat of Nef selectively regulate MHC-I trafficking. J. Virol. 73 (3),
1964–1973.
O'Neill, E., Kuo, L.S., Krisko, J.F., Tomchick, D.R., Garcia, J.V., Foster, J.L.,
2006. Dynamic evolution of the human immunodeficiency virus type 1
pathogenic factor, Nef. J. Virol. 80 (3), 1311–1320.
Piguet, V., Wan, L., Borel, C., Mangasarian, A., Demaurex, N., Thomas, G.,
Trono, D., 2000. HIV-1 Nef protein binds to the cellular protein PACS-1 to
downregulate class I major histocompatibility complexes. Nat. Cell Biol. 2
(3), 163–167.
Renkema, G.H., Manninen, A., Saksela, K., 2001. Human immunodeficiency
virus type 1 Nef selectively associates with a catalytically active
subpopulation of p21-activated kinase 2 (PAK2) independently of PAK2
binding to Nck or beta-PIX. J. Virol. 75 (5), 2154–2160.
Roeth, J.F., Collins, K.L., 2006. Human immunodeficiency virus type 1 Nef:
adapting to intracellular trafficking pathways. Microbiol. Mol. Biol. Rev. 70
(2), 548–563.Ross, T.M., Oran, A.E., Cullen, B.R., 1999. Inhibition of HIV-1 progeny virion
release by cell-surface CD4 is relieved by expression of the viral Nef protein.
Curr. Biol. 9 (12), 613–621.
Sawai, E.T., Baur, A., Struble, H., Peterlin, B.M., Levy, J.A., Cheng-Mayer, C.,
1994. Human immunodeficiency virus type 1 Nef associates with a cellular
serine kinase in T lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 91 (4),
1539–1543.
Schwartz, O., Marechal, V., Le Gall, S., Lemonnier, F., Heard, J.M., 1996.
Endocytosis of major histocompatibility complex class I molecules is
induced by the HIV-1 Nef protein. Nat. Med. 2 (3), 338–342.
Swigut, T., Alexander, L., Morgan, J., Lifson, J., Mansfield, K.G., Lang, S.,
Johnson, R.P., Skowronski, J., Desrosiers, R., 2004. Impact of Nef-
mediated downregulation of major histocompatibility complex class I on
immune response to simian immunodeficiency virus. J. Virol. 78 (23),
13335–13344.
Wei, B.L., Arora, V.K., Foster, J.L., Sodora, D.L., Garcia, J.V., 2003. In vivo
analysis of Nef function. Curr. HIV Res. 1 (1), 41–50.
Williams, M., Roeth, J.F., Kasper, M.R., Fleis, R.I., Przybycin, C.G., Collins,
K.L., 2002. Direct binding of human immunodeficiency virus type 1 Nef to
the major histocompatibility complex class I (MHC-I) cytoplasmic tail
disrupts MHC-I trafficking. J. Virol. 76 (23), 12173–12184.
Williams, M., Roeth, J.F., Kasper, M.R., Filzen, T.M., Collins, K.L., 2005.
Human immunodeficiency virus type 1 Nef domains required for disruption
of major histocompatibility complex class I trafficking are also necessary for
coprecipitation of Nef with HLA-A2. J. Virol. 79 (1), 632–636.
Wiskerchen, M., Cheng-Mayer, C., 1996. HIV-1 Nef association with cellular
serine kinase correlates with enhanced virion infectivity and efficient
proviral DNA synthesis. Virology 224 (1), 292–301.
